Thermo Fisher’s Quarterly Beat Relied Partly on One-Time Tariff Refunds
Thermo Fisher reported third-quarter adjusted earnings of $6.68 per share versus the $6.40 consensus, with revenue up 9% to $12.14 billion, but the stock moved only slightly. About $0.15 of the earnings beat came from one-time tariff refunds, so excluding them adjusted EPS would have been roughly $6.53 and margin expansion would have been smaller. The company raised its 2026 adjusted EPS guidance midpoint by $0.15, including $0.05 tied to leftover tariff money, while free cash flow through September rose 39% to $4.6 billion.
Thermo Fisher’s CFO attributed $0.26 of EPS upside versus internal guidance to three sources: $0.08 from operations, $0.03 from currency, and $0.15 from tariff refunds absent from the forecast. Those refunds contributed roughly $60 million to adjusted operating income and 50 basis points of margin.
Organic revenue exceeded guidance by about two points, helped by 10% growth in Laboratory Products and Biopharma Services; some Pharma Services revenue shifted into Q3 from Q4. Through September, free cash flow was $4.6 billion, up from $3.3 billion, and the full-year target rose to $7.0–$7.5 billion.
The one-time tariff refunds may make Thermo Fisher’s profit growth look stronger than its underlying operations, which could matter to investors assessing sustainability and to employees and suppliers tied to its spending plans. Because the company supplies laboratories and biopharma customers, its organic demand and cash generation may influence investment in research and healthcare services, though the quarter’s modest stock reaction suggests markets see limited immediate societal effect.